Drug Profile
CP 870893
Alternative Names: CP-870,893Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Developer H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (USA); Pfizer; Sir Charles Gairdner Hospital
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD4 antigen inhibitors; CD40 antigen inhibitors; Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malignant melanoma
- Discontinued Mesothelioma; Pancreatic cancer; Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Late-stage disease, Adjuvant therapy) in USA (IV, Infusion)
- 31 Aug 2012 CP 870893 licensed to VLST Corporation worldwide
- 31 Aug 2012 VLST Corporation plans a Phase-II trial for Cancer in USA